StockNews.com Lowers Vanda Pharmaceuticals (NASDAQ:VNDA) to Hold

StockNews.com lowered shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a hold rating in a report released on Monday.

Separately, TheStreet lowered shares of Vanda Pharmaceuticals from a c- rating to a d rating in a research note on Thursday, February 8th.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $4.80 on Monday. The firm has a 50-day moving average of $4.25 and a two-hundred day moving average of $4.07. The stock has a market cap of $276.19 million, a P/E ratio of 96.02 and a beta of 0.76. Vanda Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $45.27 million during the quarter, compared to analysts’ expectations of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. As a group, equities analysts expect that Vanda Pharmaceuticals will post -0.06 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. CWM LLC raised its stake in shares of Vanda Pharmaceuticals by 61.1% in the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 2,732 shares in the last quarter. Barclays PLC raised its stake in shares of Vanda Pharmaceuticals by 2.6% in the 3rd quarter. Barclays PLC now owns 128,330 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 3,265 shares in the last quarter. Swiss National Bank raised its stake in shares of Vanda Pharmaceuticals by 3.4% in the 3rd quarter. Swiss National Bank now owns 126,300 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 4,100 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the period. Finally, New York State Common Retirement Fund raised its stake in Vanda Pharmaceuticals by 57.1% during the third quarter. New York State Common Retirement Fund now owns 17,805 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 6,470 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.